{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T09:13:17Z","timestamp":1707901997702},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["transplantation-proceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.transproceed.2014.10.052","type":"journal-article","created":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T03:15:42Z","timestamp":1429240542000},"page":"809-814","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Two Patients Treated With Simeprevir Plus Pegylated-Interferon and Ribavirin Triple Therapy for Recurrent Hepatitis C After Living Donor Liver Transplantation: Case Report"],"prefix":"10.1016","volume":"47","author":[{"given":"T.","family":"Kawaoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Naeshiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.N.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Aikata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Ohdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2014.10.052_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4161\/psb.6.1.14148","article-title":"Changes in rupture formation and zonary region stained with evans blue during the recovery process from aluminum toxicity in the pea root apex","volume":"6","author":"Motoda","year":"2011","journal-title":"Plant Signal Behav"},{"key":"10.1016\/j.transproceed.2014.10.052_bib2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis c: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2014.10.052_bib3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2014.10.052_bib4","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 practice guideline by the american association for the study of liver diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2014.10.052_bib5","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis c virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2014.10.052_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0168-8278(00)80231-7","article-title":"HCV-related fibrosis progression following liver transplantation: increase in recent years","volume":"32","author":"Berenguer","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.transproceed.2014.10.052_bib7","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis c infection and survival after orthotopic liver transplantation","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.transproceed.2014.10.052_bib8","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1053\/j.gastro.2012.02.011","article-title":"Viral hepatitis in liver transplantation","volume":"142","author":"Crespo","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.transproceed.2014.10.052_bib9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1600-6143.2007.02126.x","article-title":"Clinical benefits of antiviral therapy in patients with recurrent hepatitis c following liver transplantation","volume":"8","author":"Berenguer","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2014.10.052_bib10","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s10620-009-0982-2","article-title":"Antiviral treatment of patients with recurrent hepatitis c after liver transplantation with pegylated interferon","volume":"55","author":"Schmidt","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10.1016\/j.transproceed.2014.10.052_bib11","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/lt.23542","article-title":"Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data","volume":"18","author":"Werner","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2014.10.052_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24443","article-title":"Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus","volume":"54","author":"Garg","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2014.10.052_bib13","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/lt.23669","article-title":"Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis c genotype 1 after liver transplantation","volume":"19","author":"Pungpapong","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2014.10.052_bib14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/hepr.12296","article-title":"Two patients treated with pegylated interferon\/ribavirin\/telaprevir triple therapy for recurrent hepatitis c after living donor liver transplantation","volume":"44","author":"Kawaoka","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.transproceed.2014.10.052_bib15","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1517\/14656566.2013.850074","article-title":"Simeprevir for the treatment of chronic hepatitis c","volume":"14","author":"You","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.transproceed.2014.10.052_bib16","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (tmc435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis c: the randomized pillar study","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2014.10.052_bib17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2009.10.033","article-title":"Rapid HCV-RNA decline with once daily tmc435: a phase i study in healthy volunteers and hepatitis c patients","volume":"138","author":"Reesink","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.transproceed.2014.10.052_bib18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","article-title":"Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase iib trial","volume":"146","author":"Zeuzem","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.transproceed.2014.10.052_bib19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00535-013-0875-1","article-title":"Once-daily simeprevir (tmc435) with peginterferon\/ribavirin for treatment-naive hepatitis c genotype 1-infected patients in Japan: the dragon study","volume":"49","author":"Hayashi","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.transproceed.2014.10.052_bib20","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3109\/00365521.2010.505657","article-title":"Prolongation of interferon therapy for recurrent hepatitis c after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and ns5a regions of hepatitis c virus","volume":"45","author":"Kawaoka","year":"2010","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.transproceed.2014.10.052_bib21","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/lt.21635","article-title":"Hepatitis c virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis","volume":"14","author":"Roche","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2014.10.052_bib22","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/lt.21184","article-title":"Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C","volume":"13","author":"Saab","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2014.10.052_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2036.2008.03761.x","article-title":"Clinical trial: Peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis c recurrence after liver transplantation","volume":"28","author":"Lodato","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.transproceed.2014.10.052_bib24","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/j.1600-6143.2011.03508.x","article-title":"Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS\/OPTN database","volume":"11","author":"Irish","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2014.10.052_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2014.10.052_bib26","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hep.24724","article-title":"Dual therapy with the nonstructural protein 5a inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders","volume":"55","author":"Chayama","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2014.10.052_bib27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","article-title":"Characterization of virologic escape in hepatitis c virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir","volume":"58","author":"Karino","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.transproceed.2014.10.052_bib28","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1128\/AAC.01035-12","article-title":"Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV ns5b nucleoside polymerase inhibitor mericitabine and the ns3\/4 protease inhibitor danoprevir","volume":"56","author":"Le Pogam","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.transproceed.2014.10.052_bib29","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.3748\/wjg.v17.i47.5184","article-title":"Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients","volume":"17","author":"Abu-Mouch","year":"2011","journal-title":"World J Gastroenterol"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134514012433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134514012433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T12:56:12Z","timestamp":1537707372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134514012433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0041134514012433"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2014.10.052","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two Patients Treated With Simeprevir Plus Pegylated-Interferon and Ribavirin Triple Therapy for Recurrent Hepatitis C After Living Donor Liver Transplantation: Case Report","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2014.10.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}